Raltitrexed: Thymidylate Synthase Inhibitor for Research

Raltitrexed is a water-soluble, quinazoline-based antifolate that selectively inhibits thymidylate synthase (TS), a critical enzyme in de novo DNA synthesis, making it a valuable tool compound in oncology and cell biology research.

Chemical Class

Quinazoline antifolate (folate analog)

Primary Target

Thymidylate synthase (TS, EC 2.1.1.45)

Mechanism of Action

Inhibits TS after intracellular polyglutamation, blocking dTMP biosynthesis and causing DNA synthesis arrest

Solubility

Water-soluble; typically solubilized in aqueous buffers or DMSO for in vitro studies

Research Applications

In vitro cytotoxicity assays, cell cycle analysis, enzyme inhibition studies, combination chemotherapy modeling

CAS Number

112887-68-0

What Is Raltitrexed? Structure and Biochemical Background

Raltitrexed (INN; also known by the trade name Tomudex®) is a direct, specific inhibitor of thymidylate synthase (TS), an enzyme essential for the de novo synthesis of thymidine monophosphate (dTMP). It belongs to the quinazoline class of antifolate compounds and was designed as an improvement over classical antifolates such as methotrexate, with enhanced selectivity for TS over other folate-dependent enzymes.

Structurally, raltitrexed is a quinazoline derivative bearing a glutamate side chain, which is critical for its cellular uptake via the reduced folate carrier (RFC) and subsequent intracellular polyglutamation by folylpolyglutamate synthetase (FPGS). Polyglutamated forms exhibit substantially prolonged intracellular retention and markedly increased potency against TS, underpinning the compound's utility as a long-acting research probe for TS-dependent pathways.

Its CAS number is 112887-68-0, and the molecular formula is C₂₁H₂₂N₄O₆S. These characteristics make it a well-defined, reproducible research reagent suitable for biochemical and cell-based studies.

Mechanism of Action: How Raltitrexed Inhibits DNA Synthesis

The antiproliferative mechanism of raltitrexed involves several sequential steps. First, the compound enters cells primarily via the reduced folate carrier (RFC, SLC19A1), a high-affinity transporter expressed broadly across mammalian cell types. Once intracellular, raltitrexed is converted by FPGS into polyglutamated metabolites, with each additional glutamate residue conferring tighter binding to TS and preventing efflux from the cell.

Polyglutamated raltitrexed binds to the folate cofactor site of TS in a ternary complex together with the nucleotide substrate 2'-deoxyuridine-5'-monophosphate (dUMP), forming a stable, covalent-like inhibited complex. This blocks the conversion of dUMP to dTMP, depleting the intracellular thymidine pool required for DNA replication and repair. The resulting nucleotide imbalance triggers DNA strand breaks, S-phase arrest, and ultimately apoptosis in rapidly proliferating cells.

Because TS is the sole de novo source of dTMP in mammalian cells, raltitrexed-mediated inhibition is particularly cytotoxic to cells with high proliferative rates, providing a rationale for its use in modeling therapeutic selectivity. Researchers also exploit this mechanism to study DNA damage response pathways, cell cycle checkpoints, and resistance mechanisms involving TS gene amplification or reduced RFC expression.

Research Applications of Raltitrexed

In vitro cytotoxicity and proliferation assays: Raltitrexed is widely used to establish dose-response relationships in cancer cell lines, particularly colorectal, breast, and lung cancer models. Standard assays (MTT, CellTiter-Glo, colony formation) are used to determine IC₅₀ values and assess cell viability following TS inhibition.

Cell cycle and apoptosis studies: Because raltitrexed reliably arrests cells in S phase, it serves as a valuable synchronization or perturbation agent in flow cytometry-based cell cycle analyses. Annexin V/PI staining following raltitrexed treatment can delineate apoptotic pathways downstream of nucleotide depletion.

Combination regimen modeling: Raltitrexed is frequently combined with oxaliplatin, irinotecan, or other agents in research models to investigate synergistic or antagonistic interactions. Such studies inform the mechanistic basis of clinical combination regimens for colorectal cancer.

Enzyme inhibition and biochemical assays: Purified TS enzyme can be used with raltitrexed to generate inhibition kinetics data (K_i, IC₅₀), supporting structure-activity relationship (SAR) studies and the development of next-generation antifolates.

Resistance mechanism studies: By exposing cell lines to increasing concentrations of raltitrexed, researchers can generate resistant subclones to study mechanisms including TS overexpression, RFC downregulation, and impaired FPGS activity — all relevant to clinical antifolate resistance.

Handling, Storage, and Preparation Guidelines

Storage: Raltitrexed powder should be stored in a cool, dry environment, protected from light and moisture. Refer to the product-specific Certificate of Analysis (CoA) supplied with Aladdin Scientific SKU R129835 for confirmed storage temperature and shelf-life data.

Stock solution preparation: Raltitrexed is water-soluble and can typically be dissolved in sterile phosphate-buffered saline (PBS) or DMSO at concentrations suitable for stock preparation (commonly 10–50 mM). For cell-based assays, DMSO stocks should be diluted to ensure a final DMSO concentration ≤0.1% to avoid solvent cytotoxicity artifacts. Always prepare fresh working dilutions or aliquot stocks to avoid repeated freeze-thaw cycles.

Handling precautions: As a cytotoxic antifolate compound, raltitrexed should be handled following standard laboratory safety practices. Use appropriate personal protective equipment (PPE), including nitrile gloves and lab coat. Work in a well-ventilated area or biosafety cabinet when preparing solutions. Dispose of waste according to local institutional and regulatory guidelines for cytotoxic chemical waste.

Quality verification: Confirm purity by HPLC or NMR data provided in the CoA. For critical biochemical studies, reconstitute a small pilot aliquot and verify solubility and activity before committing full stock volumes to experiments.

Raltitrexed vs. Other Thymidylate Synthase Inhibitors

Several antifolates target TS, and researchers should understand how raltitrexed compares to related compounds when selecting a tool compound.

5-Fluorouracil (5-FU): 5-FU is a pyrimidine analog that acts as a prodrug; its active metabolite FdUMP forms a covalent ternary complex with TS, similar to raltitrexed but mechanistically distinct. 5-FU additionally incorporates into RNA, contributing to cytotoxicity through multiple pathways. Raltitrexed is considered more TS-selective and mechanistically cleaner for pure TS-inhibition studies.

Pemetrexed: Pemetrexed is a multi-targeted antifolate that inhibits not only TS but also dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). Raltitrexed offers greater TS specificity, making it preferable when the research question specifically concerns TS biology.

Methotrexate (MTX): MTX primarily targets DHFR, with secondary effects on TS mediated through folate cofactor depletion. Raltitrexed's direct, potent TS inhibition is mechanistically distinct and avoids the broader off-target enzymatic inhibition profile of MTX.

In summary, raltitrexed remains the benchmark direct TS inhibitor for research applications where mechanistic clarity and TS selectivity are paramount.

Frequently asked questions

What is the recommended solvent for preparing Raltitrexed stock solutions?

Raltitrexed is water-soluble and is commonly dissolved in sterile PBS or DMSO to prepare stock solutions. For cell-based assays, ensure that DMSO is diluted to a final concentration of ≤0.1% in culture media to prevent solvent-related cytotoxicity. Consult the Aladdin Scientific product CoA for lot-specific solubility data.

How does Raltitrexed differ from 5-Fluorouracil in its mechanism of TS inhibition?

Both compounds inhibit thymidylate synthase, but via distinct mechanisms. Raltitrexed is a direct, quinazoline-based antifolate that requires intracellular polyglutamation for full activity and forms a stable ternary complex at the TS folate-binding site. 5-Fluorouracil, by contrast, is a pyrimidine analog prodrug whose active metabolite FdUMP binds at the TS nucleotide substrate site; additionally, 5-FU produces RNA-directed toxicity that is absent with raltitrexed. This makes raltitrexed more suitable for studies requiring pure TS-pathway specificity.

What cell biology assays are commonly used with Raltitrexed?

Raltitrexed is commonly used in MTT, MTS, or CellTiter-Glo proliferation/viability assays to determine IC50 values; flow cytometry-based cell cycle analysis (propidium iodide staining) to confirm S-phase arrest; and Annexin V/PI apoptosis assays to characterize cell death. It is also used in colony formation assays and, in combination studies, alongside other chemotherapeutic agents to assess drug interaction (synergy/antagonism) using methodologies such as the Chou-Talalay combination index.

What resistance mechanisms are associated with Raltitrexed?

Resistance to raltitrexed in research models has been associated with multiple mechanisms: amplification or upregulation of the TS gene (increasing the target enzyme level), reduced expression or mutation of the reduced folate carrier (RFC/SLC19A1) impairing cellular uptake, and decreased FPGS activity reducing polyglutamation efficiency. These resistance mechanisms are actively studied using raltitrexed-resistant cell sublines generated through stepwise dose escalation protocols.

References

1. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Research. 1991;51(20):5579–5586.
2. Cunningham D, Zalcberg J, Maroun J, et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. European Journal of Cancer. 2002;38(4):478–486.
3. Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Journal of Clinical Oncology. 1998;16(8):2943–2952.
4. Takemura Y, Jackman AL. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anti-Cancer Drugs. 1997;8(1):3–16.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.